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ABSTRACT
The purpose of this review is to provide a comprehensive approach for assessing the upper extremity (UE)
after stroke. First, common upper extremity impairments and how to assess them are briefly discussed. While
multiple UE impairments are typically present after stroke, the severity of one impairment, paresis, is the primary
determinant of UE functional loss. Second, UE function is operationally defined and a number of clinical measures are
discussed. It is important to consider how impairment and loss of function affect UE activity outside of the clinical
environment. Thus, this review also identifies accelerometry as an objective method for assessing UE activity in daily
life. Finally, the role that each of these levels of assessment should play in clinical decision making is discussed in order
to optimize the provision of stroke rehabilitation services.

ASSESSMENT OF UPPER EXTREMITY IMPAIRMENTS POST STROKE
Common upper extremity (UE) impairments after stroke include: paresis, loss of fractionated movement,
abnormal muscle tone and/or changes in somatosensation. These impairments are a result of direct damage to the
primary motor cortex, the primary somatosensory cortex, secondary sensorimotor cortical areas, subcortical
structures, and/or the corticospinal tract. The evaluation determines the presence and severity of each impairment
and how the impairments are contributing to loss of movement and function. Systematic, routine measurement of
impairments are critical for clinical decision making 1-3. Each impairment is discussed below and common methods
used for assessment are provided in Table 1.
Paresis
The most common motor impairment seen after stroke is paresis4. Paresis is a decreased ability to volitionally
activate motor units 5-10 and is caused by damage to the corticospinal system (the primary motor cortex, non-primary
cortical motor areas, corticospinal tract). Poor or absent volitional control of motor units means that muscles and sets
of muscles cannot be activated in a timely, coordinated manner nor activated with sufficient force 11-21. Clinically,
paresis appears as weakness and results in slower, less accurate, and less efficient movements compared to those in
neurologically-intact individuals 22, 23. A stroke will cause paresis on one side of the body, contralateral to the lesioned
brain, i.e. hemiparesis. Individuals with mild paresis will have movements that appear to be normal or near normal,
while those with severe paresis, or plegia, may not be able to move at all. Contrary to common perception, it has been
shown that the severity of paresis is similar across all segments of the UE and is not worse at the distal segments
compared to proximal ones 24, 25.
Loss of Fractionated Movement
Fractionation of movement is the ability to voluntarily move one segment independently of other segments.
Like paresis, fractionated movement deficits may be present after stroke damages the corticospinal system. The
corticospinal system is the primary neural substrate for the enormous repertoire of complex, skilled movements
humans can perform with the upper extremities 26, 27. Stroke-induced damage results in a decreased ability to
selectively activate muscles 16, 21, 28; this is the same phenomenon as the “associated reactions” and “abnormal
1

synergies” commonly described after stroke 29. Loss of ability to fractionate movement is also not specific to distal
segments but has been demonstrated across all segments of the UE 30. For example, inadvertent flexion of the
shoulder, wrist, and/or fingers may occur during instructed or voluntary flexion of the elbow. Because fractionation of
movement is essential for skilled UE motor control 26, a reduced ability to fractionate movement can limit function.
Abnormal Muscle Tone
Muscle tone is the resistance of muscle to passive elongation or stretch 31. There is a broad range of normal
muscle tone seen in healthy individuals. Abnormal muscle tone is often separated into two major categories:
hypotonicity and hypertonicity. Hypotonicity is reduced muscle tone resulting from a decreased or absent neural drive
to the muscle 32. It is often seen acutely after stroke as a result of damage to the corticospinal neurons, appearing as a
decreased resistance to passive movement and a decreased or absent stretch reflex response 33. Hypertonicity, also
referred to as spasticity or hyperreflexia, is increased muscle tone resulting from a loss of inhibition to the spinal cord
as a result of damage to the corticospinal tract. Clinically, hypertonicity can be seen as an increased resistance to
passive movement (spasticity = the velocity-dependent resistance) and an increased stretch reflex response 33. In this
case the limb may be harder to move and range of motion may be limited. Typically after stroke, hypotonicity is seen
first, and then hypertonicity develops during the first few weeks and months.
Loss of Somatosensation
If stroke damages the ascending somatosensory pathways and/or the somatosensory cortical areas, then
individuals will have a reduction or loss of somatosensation. As a consequence of this loss, the nervous system has less
ability to monitor and correct movement. The clinical picture of somatosensory loss due to stroke is global, generally
affecting an entire side of the body. There are numerous impairment-based measures that exist to assess impairments
of somatosensory modalities (light touch, joint position sense, vibration, etc.). The modality most often tested by
occupational and physical therapists is light touch 34. People post-stroke who have somatosensory loss in one
modality, such as light touch, typically have somatosensory loss in other modalities, such as proprioception 35. It is
therefore reasonable in people post-stroke to do a quick screen of one somatosensory modality, light touch, on only
one or two places on the affected limb.
2

CONTRIBUTIONS OF UPPER EXTREMITY IMPAIRMENTS TO LOSS OF FUNCTION POST STROKE
Although each of the impairments listed above can occur in isolation, more often they exist in combinations.
This is because the stroke-induced impairments are either caused by damage to the same neurological structures (e.g.
paresis, loss of fractionated movement, and abnormal tone due to damage to the corticospinal system) or caused by
damage to adjacent structures (e.g. paresis and loss of somatosensation due to damage to the primary motor cortex
and its neighbor, the primary somatosensory cortex). Thus, the severity of impairments is generally similar. In the UE,
the severity of paresis is highly correlated with the ability to make fractionated movement 30. Similarly, the degree of
spasticity, or abnormal muscle tone matches reasonably well to the severity of paresis 30. People with more severe
paresis and hypertonicity have less ability to fractionate movement, and people with more mild paresis and minimal
hypertonicity can make well-fractionated movements. While there are some cases of severe paresis (plegia) and
hypotonicity (flaccidity), these are less commonly seen than cases with severe paresis and severe hypertonicity
(spasticity).
An essential issue in the assessment of the UE post stroke is how the presence of various impairments
contributes to loss of UE function. Here, we use the term function to indicate the capacity to perform activities with
the UE. Our laboratory has studied this issue in multiple samples over the past 6 years. Rather surprisingly, our results
are remarkably consistent and show that paresis is the biggest contributor to loss of UE function post stroke 24, 25, 30, 36,
37

. Figure 1 is a schematic representation of these data. Three important points are illustrated in the figure. First, at

nearly all time points post stroke, the severity of paresis can explain the majority of variance in UE function (Figure 1A).
While other impairments were related to function, they were not as strongly related and did not explain any additional
variance, beyond that accounted for by paresis. This finding makes intuitive sense – if segments of the limb cannot
move or move much, then function will be absent or poor. Second, loss of UE function stems from paresis across the
limb, and not paresis at just a few segments (Figure 1B). The whole limb is needed for function 38. In order to interact
with objects in the environment, the proximal segments transport and rotate the hand. This positions the hand so that
the more distal segments can then contact and interact with objects. And third, paresis a few weeks, but not a few
3

days after stroke can predict later UE function (Figure 1C). This third finding illustrates the importance of both initial
severity and rate of change of severity as prognostic indicators of eventual motor function 39 (see later discussion of
prognosis in this paper). A few days after stroke, measurements indicate the initial severity of paresis, but not the rate
of change. By 3 weeks post-stroke, measurements reflect both. In sum, paresis is the most important impairment
causing UE functional loss. It is paresis across the entire limb that leads to decreased UE function, and the severity of
paresis at 3 or more weeks post-stroke that is the strongest indicator of present and eventual UE function.

ASSESSMENT OF UPPER EXTREMITY FUNCTION IN CLINIC/LABORATORY
Restoring functional use of the UE is a key goal of people who experience a stroke. Evaluation of the affected
UE examines two key factors: 1) identification of the impairments limiting normal movement (discussed above), and 2)
the initial level of activity limitations and participation restrictions arising from these impairments. Measurements at
the activity and participation levels are important in order to address complex issues such as quality of life

40

.

Outcome assessments at the activity and participation levels are necessary for determining if the selected
rehabilitation intervention results in changes that are important to the daily life of individuals living with stroke.
A variety of measures available for assessing UE function
Numerous measures are readily available to clinicians for the evaluation of UE function post-stroke. Many of
these measures have been thoroughly evaluated for reliability and validity at multiple time points post stroke. The
measures can be generally divided into two categories: 1) performance measures, where the clinician rates or times a
series of UE actions that are performed by the patient, or self-report measures, where the clinician asks a series of
questions about UE actions that are answered verbally by the patient or by proxy. The most frequently cited UE
performance measures include the Action Research Arm Test (ARAT), Box and Blocks Test (BB), Chedoke Arm and Hand
Activity Inventory (CAHAI), Jebsen-Taylor Hand Function Test (JTT), Nine-Hole Peg Test, and the Wolf Motor Function
Test (WMFT). The most frequently cited self-report measures include the Stroke Impact Scale (SIS) and the Motor
Activity Log (MAL). There is no consensus on which measure to choose for a particular person with stroke. While
there is no single measure that encapsulates the entire range of activities performed by the UE 41, a recent review
4

suggests that the ARAT and the BB test have the strongest clinical utility 42. Once a measure is selected, the same
measure should be administered at evaluation, interim and discharge evaluations, in order to document progress or
lack thereof. Tools to evaluate UE function are described briefly below; a summary of common psychometric
properties and further details about each test are provided in Table 2.
Performance Measures
Action Research Arm Test (ARAT): Developed for patients with hemiparesis, the ARAT is a criterion-rated assessment of
UE activity limitations 43-53. The ARAT includes 19 items divided into four subscales: grasp, grip, pinch, and gross
movement. The items within each subtest are ordered based on a 4-point ordinal scale ranging from 0 to 3 where 3
represents normal performance on each item. The items are arranged in a hierarchy, permitting skipping some items if
the person is unable to do an earlier item or performs an earlier item normally. A score of 57 indicates normal
performance.
Box and Block Test (BB): The Box and Block test is a quick and easy to administer assessment designed to quantify UE
activity limitations by a person’s ability to grasp, transport, and release small blocks 53-56. Individuals are asked to move
as many one-inch blocks across the center of the test box in one minute. Performance is determined by the number of
blocks moved in one minute. Times are compared to established norms, with better performance indicated by a
higher number of blocks moved.
Chedoke Arm and Hand Activity Inventory (CAHAI): The CAHAI is a functional assessment used to determine how much
the arm and hand have recovered after stroke 57-60. The original version of the assessment is comprised of 13 items
that require the use of both arms. Each activity is rated on a 7-point quantitative scale ranging from 1= total assistance
and the weak limb performs less than 25% of the task to 7= total independence. Higher scores indicate a higher level
of functional independence. Three shortened versions of the test exist, the CAHAI-9, CAHAI-8 and CAHAI-7, if time to
complete the assessment is a concern.
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Jebsen-Taylor Hand Function Test: The Jebsen-Taylor Hand Function Test was developed to assess the use of the UE in
everyday tasks 61. There are seven tasks that are tested: writing a sentence, card turning, lifting small objects,
simulated feeding, stacking checkers, and picking up light and heavy cans. Each task is timed, and better performance
is indicated by faster times. Age- and gender-based normative values on each test are available for comparison.
Nine-Hole Peg Test: The Nine-Hole Peg test is a brief measure used to quantify hand dexterity 56, 62-65. Performance is
quantified as the time taken to place and then remove the pegs, one at a time. Times are compared to established
norms, with better performance indicated by faster times. Individuals must have some degree of volitional hand
movement for this test to be a useful tool.
Wolf Motor Function Test (WMFT): The WMFT is comprised of 15 tasks to evaluate UE impairments and activity
limitations 45, 46, 48, 66-72. Items 1-6 are timed joint-segment movements whereas items 7-15 are timed integrative
functional movements. The person is given a time on each item and a Functional Ability Score (FAS) on a 6-point scale
ranging from 0 = unable to complete the task to 5 = completes the task with normal movement. For the timed scored,
better performance is indicated by faster times. For the Functional Ability Score (FAS), better performance is indicated
by higher scores, usually represented as an average of the individual item scores.
Self-Report Measures
Motor Activity Log (MAL): The MAL is a structured interview used to assess real-world UE activity 46, 50, 73-75. An
individual is asked to rate his/her performance on how much and how well the affected UE is used during a variety of
activities typically completed in daily life. Subscores can be derived from the Quality of Movement (QOM) scale and
the Amount of Use (AOU) scale. Each scale is rated on a scale of 0 – 5 where 0= “the weaker arm was not used at all
for that activity” on the QOM scale and “did not use my weaker arm” on the AOU scale and 5= “the ability to use the
weaker arm for that activity was as good as before the stroke” on the QOM and “used my weaker arm as often as
before the stroke” on the AOU scale. Scores on each scale are calculated as the mean of the scored items attempted
with the affected arm. Averages closer to 5 indicate better quality of movement and more use of the affected
arm/hand. There are two versions of the assessment; 1) MAL-28 and the shorter 2) MAL-14.
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Stroke Impact Scale: The Stroke Impact Scale (SIS), is a stroke-specific, comprehensive health questionnaire with
subscales in eight domains: Strength, Hand function, ADL/IADL, Mobility, Communication, Emotion, Memory and
Thinking, & Participation/Role function 76-83. The individual uses a 5-point Likert scale to rate his/her ability on each
item. Questions can be administered in a face-to-face interview format, over the telephone, or via the mail. The
subscales of Hand Function and ADL/IADL are most relevant for measurement of UE function. Scores for each subscale
range from 0 – 100, with normal self-reported function indicated by a score of 100.
Relationships between measures at different time points post-stroke
Scores for many of these measures are highly inter-related, and remain so across various times post stroke.
For example, the ARAT and the WMFT have been shown to be strongly correlated with each other at 14 days, 1, 3 , and
6 months post-stroke 84. Similarly, the ARAT, Jebsen-Taylor Test of Hand Function, 9-Hole Peg Test, and the Stroke
Impact Scale – Hand Function subscale have been shown to have moderate to strong correlations at 1 month, 3
months and 6 months post-stroke 85. Relationships between these measures and others are provided in the fourth
column in Table 2. The strength and consistency of these correlations suggest that the measures quantify the same
underlying construct, i.e. UE function, and that any one of them would be appropriate for clinical use. The decision to
use one measure vs. another can therefore be made based on additional factors.
Deciding which measures to use
Since measures of UE function are highly inter-related, there is a great deal of freedom when selecting a
measure for use with a specific individual. Some therapists may use more than one measure, with one assessment
intended to quickly quantify change (e.g. BB) and another measure intended to determine which UE movements (e.g.
ARAT or WMFT) or which self-reported functional problems (e.g. MAL, SIS) need to be addressed during treatment.
Three key questions influence the selection process. Is the necessary equipment available? Is specific training needed
prior to administration? How much time does it take to administer?
Equipment: Many of the described measures are pre-made test kits that can be purchased from reputable
rehabilitation suppliers. These test kits can range in price from approximately $50 up to several hundred dollars. Both
7

the ARAT and the WMFT test kits can be built relatively economically based on descriptions in published articles or
manuals available on the internet. A good source for information about the tools and what each tool looks like is
http://www.medicine.mcgill.ca/strokengine-assess/, a web-site sponsored by the Canadian Stroke Network.
Availability of measures will vary from facility to facility. For instance one facility may have the Jebsen-Taylor test
while another facility may own the ARAT. Because these measures are similar assessments of UE function, then
choosing the test that is readily available at one’s workplace is a logical basis for test selection.
Training: Often measures require that the administering clinician take part in a formalized training program in
order to be certified to use the measure. Each of the performance assessments discussed in this manuscript do not
require additional training in order to perform them. Some assessments, like the CAHAI provide training videos for a
nominal fee (available online). For other assessments, like the ARAT, there is are published instructions available that
can be followed to ensure stable performance 86. For most of the measures discussed here, carefully reading the
instruction manual and practicing administration of the test will result in the measure being administered correctly.
Time: The amount of time required to administer a measure will strongly influence whether or not it is
selected for use in routine clinical practice. Measures that take a shorter amount of time are more likely to be used.
The second column in Table 2 provides an estimate of the time needed to administer each of the measures. Note that
it usually takes longer to administer any measure when one first starts using it. As familiarity with the items and
instructions increases, the time to administer the measure usually decreases. Clinical facilities often prescribe the
amount of time available for an evaluation. While it is compelling to always choose the shortest measures (e.g. Box
and Block or Nine-Hole-Peg tests), the longer measures often yield additional valuable information. The short
measures require performance of only one action. The longer measures (e.g. ARAT and WMFT) evaluate performance
on more actions. In addition to the total score on the longer measures, observing the person with stroke interact with
a variety of objects during administration of the longer measures will allow the treating clinician to see exactly which
components of movement (e.g. types of grasps) and how (e.g. with large objects, cannot extend fingers sufficiently)

8

movement components are affected. These observations can facilitate treatment planning, providing information on
how to structure movement practice.

ASSESSMENT OF UPPER EXTREMITY USE OUTSIDE THE CLINIC/LABORATORY
Assessment of the affected UE in the clinic or laboratory includes measures of impairments, measures of
performance, and self-report questionnaires. Outside the clinic however, direct observation of impairment and
performance is costly and impractical, leaving self-report measures as one of the only options. Although self-report
measures are often selected due to ease of administration, they are: 1) affected by comprehension, memory recall,
and motivation 87, 88; 2) unreliable when used with persons who have cognitive deficits in memory and attention, as
commonly experienced by persons with stroke 89; and 3) at best are moderately correlated with direct methods of
activity measurement 90. Furthermore, improvement on measures of function following rehabilitation has been shown
to lack association with increased UE use at home 91. Because improvement in daily function at home is the goal of
rehabilitation, it is important that objective assessment tools be used to measure UE use during real-world activity
outside of the clinic. One such tool is the accelerometer.
How accelerometers measure upper extremity use
Accelerometers measure movement in terms of acceleration. Acceleration is the change in speed with respect
to time, and is measured in gravitational acceleration units (g; 1 g=9.8 m/s²). This is done by converting mechanical
motion into electrical signals, often via piezoelectric sensors. The sensors are contained within a device which is
similar in size to a wristwatch (Figure 2A) and can be comfortably worn on the wrist 92. The electrical signal is
converted to a digital signal called an activity count, quantifying how much movement occurred during a specific time
period, called an epoch 93. The epoch is chosen by the clinician, and can be as short as a second or as long as a few
minutes (e.g. the length of a specific activity). One way to measure UE use is to sum activity counts per epoch as a
measure of intensity of UE use. Another way to measure UE use is to choose a small epoch, such as one second, and
determine if movement occurred during that epoch. This is done by “filtering” activity counts: if an activity count
occurred during a one-second epoch, then movement occurred during the epoch; if an activity count did not occur
9

during the epoch, then movement did not occur during the epoch 94. In this way, epochs where the UE was used can
be summed to determine the amount of UE use during a given time period, such as hours in a day. Percentage of UE
use that occurred during the wearing time can also be determined. Epoch selection, filtering, and calculation of UE use
can often be done with the software program that comes with the accelerometers. Figure 2B shows an example of
what UE accelerometer data look like during a 1½ hour wearing time.
Reliability and validity of accelerometer measurement
For accelerometers to be useful, they must be reliable and valid. Studies have shown that accelerometer
activity counts are consistent for the same activity at different time points when the same accelerometer unit is used,
i.e. intra-rater reliability has been established 95. Activity counts are also consistent for the same activity when
different accelerometer units are used, i.e. inter-rater reliability has been established 95, 96. Furthermore, strong
correlations between UE accelerometer counts at separate time points indicate good test-retest reliability 97, 98.
It is well documented that accelerometry is an objective measure of UE use, i.e. construct validity has been
established. Studies show 88% agreement between UE accelerometry and observed movement by an observer, as
well as a very strong correlation (r = 0.93) between UE accelerometry and duration of movement. Accelerometry is
also able to distinguish UE use between people with and without stroke and between use of the affected and
unaffected limbs of people with stroke 99, 100. Moreover, accelerometry is sensitive to change, demonstrating increases
in activity counts following therapeutic intervention 101-103.
There is also ample agreement between accelerometry and accepted, standardized measures of activity, i.e.
convergent validity has been established. Moderate to strong correlations exist between UE accelerometry and
electromyography during activities of daily living (r = 0.53) 104, elbow electrogoniometry during daily use (r = 0.94) 105,
and standardized measures that assess impairment, function, and activity (see Table 3). Low correlations between UE
accelerometry and the mobility subscale of the Stroke Impact Scale (r = 0.16 - 0.23) indicate that UE accelerometry is
not associated with lower extremity activity

106

, thereby demonstrating divergent validity.

The utility of accelerometers for clinical practice
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Accelerometers are relatively inexpensive ($100- 500 per unit), commercially-available, and complement
information gained from other available measures. Accelerometers can be used to measure UE use during the initial
evaluation, weekly or monthly during the course of treatment, and at discharge. UE use can then be compared across
time points to assess change in use. When used this way, UE use as measured by accelerometry, is an intuitive
measure of recovery and return to daily activity and participation. The counts or amount of use generated by
accelerometers can be appreciated by the person receiving therapy services, his/her family members, other clinicians,
and third-party payers. It is relatively simple for persons receiving rehabilitation services to understand his/her UE
recovery as measured by an increase in hours of UE use in a day. These numbers are more intuitive than changes of
one or a few points on clinical rating scales. Direct measures of use may also motivate the individual and the family to
continue efforts to incorporate gains made in therapy into everyday life. Additionally, rehabilitation clinicians will
benefit from tracking change in UE use during treatment as a means of evaluating the effectiveness of the chosen
interventions. If an intervention has increased the real-world use of the affected UE, these numbers are proof of the
benefit. If an intervention has failed to increase the real-world use of the affected UE, then a different approach needs
to be selected or therapy services need to be terminated. A quantitative measure showing increased UE use during
the course of therapy services can be submitted with other documentation when requesting additional therapy
services from a third-party payer. Our laboratory is in the process of collecting normative data with accelerometers;
these values will be useful benchmarks for assessing the extent of improvement in individual patients.
While accelerometers provide useful information, some limitations deserve consideration. Accelerometers
are electronic devices that are subject to mechanical failure and need to be checked at regular intervals. Another
limitation is that accelerometer data has to be processed by a software program. Care must be exercised when
choosing accelerometers and software programs to ensure that the user will be able to adjust program settings in
order to report activity counts in terms of UE use. Fortunately, current available software has become substantially
more user-friendly over the past 10 years, even for busy clinicians. Finally, compliance with wearing the
accelerometers may be an issue for some individuals when wearing them for a long period of time, forgetting to
replace accelerometers after removal for showering or hand washing, or cognitive deficits. Despite their limitations,
11

accelerometers are practical and useful devices that allow a clinician to collect valuable, objective information that
would be otherwise unavailable. They allow UE use to be measured outside of a clinical setting and to effectively
measure rehabilitation outcomes in the real world.

USING ASSESSMENT RESULTS TO MAKE CLINICAL DECISIONS
Results derived from both impairment and functional assessments assist the clinician with the development of
treatment plans and aid with evaluating the utility of a particular treatment. In addition to assessment results, clinical
decisions depend on the prognosis for recovery of impairments and function after stroke. Epidemiological data from
multiple countries show that recovery after stroke occurs along a fairly predictable time course. Most motor and
functional recovery will occur within the first 3 months 107, 108. Early severity of paresis is the best predictor of eventual
motor deficits and function 39, 109, 110. Those with mild deficits recover more quickly and completely, with best
neurological recovery occurring within 3 – 6 weeks 108. Those with more severe deficits recover more slowly and to a
much lesser extent, with best neurological recovery occurring within 13 – 15 weeks 108. For the purpose of predicting
recovery of individual patients, the epidemiologic data provide the general pattern of recovery and most, but not all,
patients will follow a similar time course of changes. There are three additional indicators of future outcomes that are
useful to look for when trying to determine prognosis in individuals. First, the more non-motor impairments (e.g.,
somatosensory loss or visual field loss) that accompany the motor deficits (e.g., paresis, fractionated movement
deficit), the less likely a person is to return to functional independence 111. Second, early, rapid improvements in
motor impairments are an indication that a person is more likely to reach higher levels of independence 108, 112. And
third, the absence of measurable grip strength or shoulder flexion at 3-4 weeks post stroke is a strong indicator that
the affected upper limb will be non-functional 25, 29, 110, 113. Recovery of function typically lags recovery of neurological
impairments by about 1 to 2 weeks, with the trajectory of the two recovery curves being nearly identical 108. The
reason for the 1 – 2 week lag may be that as impairments improve, practice is required to capitalize on the
neurological recovery and incorporate the improvements into daily function.
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The combination of the individual’s assessment data, the time since their stroke, and the epidemiological data
reviewed above will allow the clinician to determine: 1) whether or not more neurological recovery is expected; and 2)
whether or not more functional recovery is expected. For many individuals with stroke, motor and somatosensory
impairments will not substantially change, but activity limitations and participation restrictions can be lessened
through a course of rehabilitation. For example, a person that is 2 years post stroke with a Motricity Index of 27 (MMT
grades of 2/5 in the three candidate motions) and absent light touch sensation on the palm on their affected UE would
be expected to have no or minimal changes at the impairment level. It is highly possible however, that a course of
rehabilitation therapy with a focus on functional training for the individual and his/her family, may improve daily
activities such as bathing and dressing and may reduce caregiver assistance needed with these activities. Determining
expectations about the likelihood of neurological and functional recovery from assessment scores will facilitate: 1)
setting realistic treatment goals; and 2) selecting a restorative or compensatory approach to achieve those goals.
Choosing a restorative or a compensatory approach is critical when developing the plan of care for an
individual with stroke. A restorative approach is focused on returning or restoring the previously lost motor abilities
and function. A compensatory approach is focused on maximizing function, often with alternate strategies, within the
confines of the limited motor abilities. In managing the UE post stroke, a restorative approach would be chosen if the
person had a stroke less than 3 months earlier and assessment results indicate there is voluntary, fractionated
movement against gravity at several UE segments 114. In contrast, a compensatory approach would be chosen for a
person with minimal or no voluntary, fractionated movement, whether early or later poststroke 114. The expectation
for the restorative approach is that a course of rehabilitation will return the arm and hand to a reasonable, functional
level of dexterity. The expectation for the compensatory approach is that a course of rehabilitation will educate the
individual to minimize contracture development, edema, and potential hygiene problems, and possibly permit the arm
and hand to be used as an assist during functional activities. In the neurological therapy world, there is an oftenvoiced concern that the decision to use a compensatory approach will limit a person’s eventual recovery. There is
limited empirical data to support this concern. In fact, results from the VECTORS trial, a Phase II trial evaluating
constraint induced movement therapy in the inpatient rehabilitation setting, suggest otherwise 115. In this study, the
13

experimental group received focused training aimed at restoring normal movement of the affected limb while the
control group received general training and could not be cued to use their affected limb or told to use it in a specific
way. UE function improved to a similar degree in these two dose-matched groups, and scores were equivalent at the
end of the intervention and at 3 months post stroke. An equal but less discussed concern is that the decision to use a
restorative approach could waste valuable therapy time, leaving a person with stroke ill-equipped to function in daily
life once the course of therapy is completed. There is no easy answer to these competing concerns. Frequent reassessment of key impairments and activity limitations will enable the clinician to determine if the appropriate
approach was chosen and if a switch to the alternate approach is needed.
Specific interventions are chosen once the approach has been determined. Interventions for the UE poststroke are generally targeted toward improving function and not targeted at improving impairments in isolation 114, 116.
The challenge to the clinician lies in selecting and structuring functional training to address the movement dysfunction
(restorative and compensatory approaches) and underlying impairments (restorative approach only). For example, if
the individual’s goal is to return to gardening activities, then therapy sessions and the home exercise program would
be used to practice (or simulate practice of) various aspects of gardening such as grasping and using tools, digging, and
moving plants. If the approach is compensation, then the specific treatment will focus on executing gardening
activities safely with whatever positions (seated vs. standing), motions (primarily use unaffected hand), and assistive
devices (adaptive tools) are appropriate. If the approach is restorative, then the specific treatment will focus on
returning normal movement patterns while grasping and using gardening tools. While further discussion of specific
interventions and their evidence of benefit is beyond the scope of this chapter, the reader is encouraged to access
excellent online summaries such as the Evidence-Based Review of Stroke Rehabilitation114 (www.ebrsr.com) and the
StrokeEngine (www.strokengine.ca ).
Repeated administration of one or several measures is of great benefit to persons receiving stroke
rehabilitation and clinicians managing their rehabilitation course. For the person with stroke, an improved score (e.g. 6
kg of grip force now compared to 3 kg two weeks ago, 41/57 on the ARAT now compared to 21/57 two weeks ago) can
motivate them to continue with their long, demanding course of rehabilitation. If the scores are not improving, this
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information can affirm that their perception of stalled performance may be accurate. For the clinician, it is an
objective, quantitative method to assess progress. Data from the measures address issues of whether or not a person
is continuing to improve, whether or not the selected intervention is improving impairments and function as hoped,
and whether or not continued therapy services are warranted. Clinicians will want to select a reasonable interval for
re-assessment, i.e. a time in which improvements would be expected to occur. In short inpatient stays, now averaging
16-17 days in the United States 117, 118, formal re-assessment of UE impairments and activity restrictions may take place
in the days before discharge. These results would then be used to educate the person with stroke and his/her family,
to select appropriately graded home activities and exercises, and to provide information to the next point of care. For
outpatient services, re-assessment might be most appropriate on a monthly basis, as changes in impairment and
function will be occurring more slowly than they were immediately after stroke and visits will be one or a few times
per week. Reassessment of functional improvement is the key factor in keeping the person, family, and physician
updated on rehabilitation progress.

SUMMARY
The purpose of this review was to provide a comprehensive approach for assessing the UE after stroke.
Evaluating the presence and severity of UE impairments and function after stroke is critical for understanding not only
how well the UE is used in the clinic, but also how much the limb may be used during activities of daily living at home
or work. Many of the assessments provided in this review are reliable and valid, with high levels of consistency
(between raters and post-stroke time points) and correlation (between the assessments themselves). While knowing
what constructs are being tested by each assessment is important, knowing how these assessments provide insight
into the larger picture of UE function and recovery is useful in formulating goals and treatment plans for individuals
living with stroke.
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Table 1. Assessment of common upper extremity impairments after stroke
Impairment

Assessment

Time to
administer
3 min

Description

Reliability

Details

Paresis

Motricity Index

Manual Muscle Test Score is
given for shoulder abduction,
elbow flexion and pinch grip.
Together these scores are
converted to a total force
production score for each UE
ranging from 0 (no strength) to
100 (full strength)

Intrarater =no
established studies
Interrater ᵨ=0.88

Paresis after stroke similarly
affects movement at each
segment. This means that
one needs to test only a UE
few segments. The
Motricity Index is quick and
provides a total force score
for the entire UE.

Grip Strength
Pinch Strength

2-3 min

Intrarater r=0.80
Interater r=0.97

Observation of
fractionated
movement,
paresis
assessment
Modified
Ashworth Scale

Observed
during paresis
assessment;
5-6 min

Hand-Held Dynamometer to
assess kilograms or pounds of
force. Age- and genderappropriate normative values
available.
Presence or absence of
movement fractionation
observed; note any
substitutions or associated
reactions
Six point scale from 0 (no
increase in muscle tone) to 4
(affected part is rigid)

Measurement of handgrip
strength has been shown to
predict motor performance
and functional
independence 64, 65
As part of the paresis
assessment, fractionation of
movement can be assessed.

Intrarater =no
established studies
Interrater tau=0.85

The elbow flexors are most
easily and commonly
assessed in the UE.

Somatosen
-sation

Light Touch

1-2 min

Light touch sensation can be
noted as Intact, Impaired (i.e.
less feeling compared to other
side), or Absent based on one
light stroke to the skin of the
UE

N/A

Multiple
Impairments

Fugl-Meyer,
Upper Limb
Section 123 84

30 min

The upper limb section has 33
items including: movement
observation, reflex testing,
grasp testing and coordination.
Three point scale from 0
(unable to perform) to 2 (able
to perform) totaling 66 for the
upper limb portion.

Intrarater ICC= 0.99
Interrater ICC=0.96

Loss of somatosensation
after stroke typically occurs
across multiple modalities
and across the entire limb.
Light touch is the most
common modality assessed.
Results from a single,
representative modality at
1-2 sites are an indicator
that similar deficits exist in
other modalities and at
other locations.
The Fugl-Meyer provides a
global assessment of UE
impairment. Often a quicker
measure of paresis is
selected over the FuglMeyer to decrease testing
burden 124.

119, 120

121, 122

Fractionation
of
Movement
Muscle Tone

< 5 min

31

N/A
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Table 2. Performance and self-report measures commonly used to assess upper extremity function after stroke
Performance Assessments
Name
Time to
administer

Reliability

Relation to other
measures (Concurrent
Validity)
r=0.91-.94 with FuglMeyer;
r=0.96 with Motor
Assessment Scale ;
r=0.87 with Motricity
Index;
r = 0.93 with CAHAI

Estimate of MCID*

Strengths

Weaknesses

6 pts (chronic
stroke);
12 points (acute
stroke - dominant
hand);
17 points (acute
stroke - nondominant hand)

Quick; Easily
administered;
Appropriate at all
stages of recovery

Not commerciallyavailable, but can
be built from
published
instructions

Action Research
Arm Test

10-15 min

Intrarater r=0.99
Interrater r=0.98
Test-retest r=0.98

Box & Blocks
Test (BB)

5-10 min

r=0.92 with FuglMeyer;
r=0.95 with ARAT

6 blocks with
affected hand

Quick; Easily
administered

Requires at least
minimal distal
volitional control

Chedoke Arm
and Hand
Activity
Inventory
(CAHAI)

25 min

Intrarater ICC= no
established studies
Interrater ICC= 0.99
Test-retest ICC= 0.96
Intrarater ICC= no
established studies
Interrater ICC= 0.98
Test-retest ICC= 0.96 .97

r = 0.93 with ARAT

6.3 points

Takes longer than
other measures
that capture the
same information

Jebson-Taylor
Hand Function
Test

15-20 min

Interrater ICC= 0.821.00

rs= 0.84-.97 with 9Hole Peg Test;
rs= 0.87-.95 with ARAT

unknown

Nine-Hole Peg
Test

10 min

Interrater/Test-retest:
r= 0.68-.99

rs= 0.84-.97 with
Jebsen-Taylor
rs= 0.85-.93 with ARAT

32.8 seconds with
affected hand

Easily
administered;
Shorter versions of
the test exist if
time is a concern;
Free to use
Standardized
instructions; good
measure when the
ceiling is achieved
on other shorter
measures
Quick; Inexpensive
to purchase

Wolf Motor
Function Test

30 minutes

Interrater ICC= 0.850.97
Test-retest ICC= 0.940.99

rs= 0.86 (FAS) with
ARAT
rs= 0.89 (time) with
ARAT

1.5-2 sec (WMFT
time - chronic
stroke);
19 seconds (WMFT
time -acute
stroke);
0.2-0.4 pts
(WMFT FAS)

Self Rating Assessments
Motor Activity
15-20
Log
minutes

Standardized
instructions;
Appropriate at all
stages of recovery

Requires at least
minimal distal and
proximal volitional
control
Most appropriate
for higher
performing
individuals
Takes longer than
other measures
that capture the
same information

Test-retest ICC= 0.790.82

rs=0 .35-.39 (QOM
1.0-1.1 pts on the
Inexpensive;
Takes longer than
scale) with ARAT
quality of
Tries to capture
other interviews;
rs= 0.31-.32 (AOU
movement scale
real-world
Relies on selfscale) with ARAT
abilities; Easy to
ratings
rs= -0.26- -.33 (QOM
administer
scale) with 9-Hole Peg
Test
rs= -0.16- -.23 (AOU
scale) with 9-Hole Peg
Test
rs= -0.52 (QOM scale)
with BB
rs= -0.37-.49 (AOU
scale) with BB
r=0.52-.66 (QOM
scale) with
accelerometry
Stroke Impact
5 minutes
Test-retest:
rs= 0.57-.73 with ARAT
ADL/IADL = 5.9 pts
Inexpensive; Tries
Relies on selfScale (ADL and
each
ICC= .70-.92
rs= 0.61-.83 with
Hand function =
to capture realratings
Hand Function
subscale
Jebsen-Taylor
17.8 pts
world abilities;
rs= 0.53-.66 with 9Easy to administer
Subscales)
Hole Peg Test
*Minimal Clinically Important Difference (MCID) has been defined as “the smallest difference in score in the domain of interest which patients perceive as
beneficial and which would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient’s management” 125. Note that these
values are labeled as estimates because they are likely influenced by the time post-stroke and the severity of functional loss.
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Table 3. Relationships between accelerometry measures of upper extremity use and impairment, self-report, and performance
measures. Note that some of the performance measures specifically assess the upper extremity while others assess additional
constructs, such as mobility and activities of daily living.
CORRELATION

IMPAIRMENT MEASURES
Motricity Index
Fugl-Meyer Assessment—Arm
Section

r=0.5* 102
r =-0.851** 126
r=0.54** 127

PERFORMANCE MEASURES
Action Research Arm Test
Wolf Motor Function Test
Functional Impairment Measure
Barthel Index

r=0.40† 99
r=0.62* 99
r=0.67,* 99
ρ=0.64* 102

SELF-REPORT MEASURES
Stroke Impact Scale – Hand Function
subscale
Motor Activity Log – Quality Of
Movement scale
†=.05, *=.01, **=.001

r=0.61** 103
r=0.52** 98
r=0.66** 103
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24, 25, 30, 36-38

Figure 1. Schematic representation of data from multiple studies in our lab
. In each panel, the large, white circles
represent the construct of UE function. The size of the smaller, filled circles represent how much the impairment (A & C, paresis)
or joint (B) contributes to UE function. A: At nearly all time points post stroke, the severity of paresis can explain the majority of
variance in UE function. B: Loss of UE function stems from paresis across the limb, and not paresis at just a few joints. C: Paresis a
few weeks, but not a few days after stroke can predict later UE function. Other impairments tested included muscle tone,
fractionation of movement, and somatosensory loss. These other impairments did not add any additional contributions to UE
function in the regression models. UE = upper extremity.
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A.

B.

Figure 2. Accelerometry can be a useful tool to measure UE use outside of the clinic or laboratory. A: Picture of commerciallyavailable accelerometers worn on the wrists (GT3X+ Activity Monitor, ActiGraph, Pensacola FL). The size of each accelerometer is
4.6 cm x 3.3 cm x 1.5 cm. B: An example of what UE accelerometer data looks like. The date of the recording is provided at the
top, and data is shown from 2:30 pm to 4:00 pm. The data line indicates the count or how much the limb was moving during this
1.5 hour period. Moments when the line is equal to zero indicate times when the limb was not moving.
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